Key result
Non-invasive HEMOTAG device detects ADHF with 95% sensitivity using prolonged IVCT.
Why the study?
Does non-invasive measurement of isovolumetric contraction time using the HEMOTAG device correlate with NT-proBNP levels and treatment response in patients with acutely decompensated heart failure?
Observational (n=105)
Unblinded
No
Does non-invasive measurement of isovolumetric contraction time using the HEMOTAG device correlate with NT-proBNP levels and treatment response in patients with acutely decompensated heart failure?
Answers are grounded in this paper and cite their sources.
Non-invasive measurement of isovolumetric contraction time using the HEMOTAG wearable device correlates with NT-proBNP trends and may offer a novel method to monitor treatment response in acutely decompensated heart failure.
recording device-A non-invasive, wearable system that measures cardiac time intervals (CTIs)-in managing patients with acutely decompensated heart failure (ADHF). The prospective, single-center study enrolled 105 patients, including those hospitalized with ADHF and a control group with non-HF-related conditions. Daily measurements of isovolumetric contraction time (IVCT), a key CTI marker, were collected using the HEMOTAG device and compared with NT-proBNP levels obtained on admission and day 3. Among ADHF patients, IVCT decreased in parallel with NT-proBNP levels, indicating volume status improvement with therapy. In contrast, the control group showed no significant change in IVCT or NT-proBNP. An IVCT ≥ 40 ms demonstrated strong sensitivity and specificity to detect ADHF (NT-proBNP ≥ 1800 pg/mL). These findings suggest that IVCT trends measured by HEMOTAG correlate with short-term treatment response in ADHF and could offer a non-invasive method to guide heart failure management. The technology demonstrated feasibility, safety, and clinical relevance, supporting its potential role in future remote management strategies.
No takes yet. Share an insight, caveat, or question.
Chait et al. (2025) conducted an observational in Acutely decompensated heart failure (ADHF) (n=105). HEMOTAG recording device vs. Hospitalized patients without a diagnosis of ADHF was evaluated on Diagnostic accuracy of isovolumetric contraction time (IVCT) ≥ 40 ms to detect ADHF (NT-proBNP ≥ 1800 pg/mL) (AUC 0.92). The non-invasive HEMOTAG device demonstrated that an isovolumetric contraction time ≥ 40 ms detected acutely decompensated heart failure with 95% sensitivity, 84% specificity, and an AUC of 0.92.
Synapse has enriched 10 related papers. Consider them for comparative context: